Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program, VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in the development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Viking Therapeutics reports solid financials and advances in clinical programs

Viking Therapeutics showcased a strong financial position and progress in clinical programs for various disorders
Challenges include observing full efficacy in short studies and balancing efficacy with safety in dose decisions
Opportunities lie in achieving target efficacy ranges, optimizing dosing based on data, and releasing comprehensive study results

Viking Therapeutics reports Q1 progress and financial stability post-offering

Viking Therapeutics showcased progress in clinical programs and financial stability post-public offering.
Analyst inquiries focused on tolerability, dosing, and expectations for top-line results of key compounds.
Challenges include managing expenses, PK/PD profile comparisons, and uncertainties in enrollment for upcoming studies.
Opportunities lie in pipeline expansions, confidence in oral formulation data, and potential combination studies for future growth.

Viking Therapeutics excels in clinical trials and financial stability

Viking Therapeutics delivered strong clinical and financial performance in Q2 2023, positioning itself well in the NASH and obesity markets.
The company's methodical approach to clinical trials and focus on internal development underscore a strategic and disciplined growth strategy.
While facing financial challenges and operational complexities, Viking has opportunities to leverage positive trial results and cash reserves for future growth.
Overall, Viking's Q2 performance reflects a balanced pursuit of innovation, financial prudence, and strategic advancement in its pipeline.

Viking Therapeutics reports robust Q3 performance and eyes combination therapies

Viking Therapeutics showcased strong clinical data and financial stability in Q3 2023, with key trials progressing as planned.
While facing challenges like limited MRI data and formulation complexities, the company's commitment to innovation and scalability remains evident.
Opportunities lie in exploring combination therapies, addressing patient preferences, and leveraging market trends for future growth.
Overall, Viking's performance, strengths, and strategic outlook position them well for continued success in the biopharmaceutical sector.

Viking Therapeutics excels in clinical trials and financial growth

Viking Therapeutics showcased positive trial results, financial strength, and a proactive approach to advancing their pipeline. While facing challenges in managing expenses and navigating regulatory requirements, the company remains optimistic about the potential of their clinical programs. Opportunities for growth exist through successful trial outcomes, strategic partnerships, and regulatory engagements.

Viking Therapeutics reports strong Q1 results and plans pipeline expansion

Viking Therapeutics showcased positive clinical outcomes for VK2735 and VK2809, supported by a successful public offering.
Financially, the company reported increased expenses but maintains a robust cash position for future development.
Challenges include managing expenses, regulatory transitions, and data reporting timelines, while opportunities lie in market expansion and regulatory advancements.
Overall, Viking's strategic focus on pipeline advancement and leveraging strong financials positions them for continued growth and success.

Viking Therapeutics advances breakthrough therapies with strong financial backing

Viking Therapeutics reported positive trial outcomes and a strong financial position, poised to advance breakthrough therapies for obesity and NASH.
While facing regulatory and financial challenges, Viking's innovative approach and diverse pipeline present opportunities for growth and strategic partnerships.
With a focus on advancing Phase III programs and exploring new treatment avenues, Viking remains well-positioned to drive therapeutic innovation and address unmet medical needs.

Viking Therapeutics excels in clinical trials and strategic partnerships

Viking Therapeutics delivered strong clinical progress and financial stability in Q3 2024, positioning itself for further growth and development. While facing cost challenges, the company is actively pursuing strategic opportunities to advance its pipeline and expand its market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE Trial of GLP-1/GIP Agonist VK2735 in Obesity Demonstrated Up to 13.1% Placebo-Adjusted Weight Loss (14.7% From Baseline) at 13 Weeks; Shown to be Safe and Well-Tolerated Results From Phase 1 Trial of Oral VK2735 Demonstrated Promising Safety and Tolerability With Up to 3.3% Placebo-Adjusted Weight Loss (5.3% From Baseline) at 28 Days 52-Week Histology Results From Phase 2b VOYAGE Study Evaluating VK2809 for the Treatment of NASH and Fibrosis Expected in 2Q24 Completed Public Offering of Common Stock Raising Gross Proceeds of Approximately $630 Million ; Quarter-End Cash Position of $963 Million SAN DIEGO , April 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on its clinical pipeline and other corporate developments.

Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intra-Cellular Therapies

Novo Nordisk

Investing in biotech stocks is not for the faint of heart. The sector is prone to wild swings in stock prices, offering a distinctive blend of high risk and high reward.

3 Biotech Stocks With Skyrocketing Potential: April 2024

Geron

Neurocrine Biosciences

The economy is currently on a stable trajectory and is poised for sustained growth; the indicators show a positive outlook overall. However, the biotech industry presents even more compelling potential, demonstrating a compounding annual growth rate (CAGR) of 13.96% from 2024 to 2030.

3 Red-Hot Biotech Rockets Blasting Off in 2024

Vertex Pharmaceuticals

Novo Nordisk has achieved tremendous success thanks largely to Ozempic and Wegovy. Vertex Pharmaceuticals is another drugmaker that could soon have two new big winners on the market.

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Pfizer

Shares of Pfizer and Viking Therapeutics have been on markedly different trajectories over the prior three years. In this comparison, Pfizer scans as a safer choice for cautious investors, while Viking Therapeutics may appeal to risk-tolerant growth investors.

Better Buy: Pfizer vs. Viking Therapeutics

Salesforce

Shopify

Many investors look to analysts' expectations to guide their movements each quarter. Typically, those investors can reasonably use estimates as a reference.

3 Stocks With the Potential to Surpass Analyst Expectations for 2024

Altimmune

GoodRx Holdings

Eli Lilly

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V NYSE: NVO with its Semaglutide medications Ozempic and Wegovy, and Eli Lilly & Co. NYSE: LLY with its Tirzepatide medications Mounjaro and Zepbound.

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

Recursion Pharmaceuticals

Sana Biotechnology

Biotech stocks are having a relatively strong year as investors focus on the growing M&A in the healthcare space. Johnson & Johnson is acquiring Shockwave Medical while Novo Nordisk is buying Catalent, a CDMO organization.

Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX

Viking Therapeutics, Inc. (VKTX) concluded the recent trading session at $63.42, signifying a -1.93% move from its prior day's close.

Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key Insights

VKTX has reported positive data from a phase 1 trial of the oral formulation of VK2735, showing a placebo-adjusted weight loss of 3.3% at the highest dose at 28 days. There was an absence of plateauing of weight loss at 4 weeks at the higher doses, meaning longer treatment could yield further weight loss. Viking plans to continue dose escalation in the current trial meaning further data might not be far ahead, especially if VKTX doses patients for just 4 weeks.

Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead

Conference Call Scheduled for Wednesday, April 24 at 4:30 p.m. Eastern Time SAN DIEGO , April 17, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will release financial results for the first quarter 2024 after the market close on Wednesday, April 24, 2024.

Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024

Amgen

AstraZeneca

Structure Therapeutics Inc

Sanofi

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

Janux Therapeutics

Investors looking for a white-knuckle ride can easily find one by buying biotech stocks. There is a certain thrill in investing in a company making actual life-or-death decisions with drugs.

These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?

CRISPR Therapeutics

CRISPR Therapeutics has significant upside potential. Eli Lilly could become an even bigger healthcare giant.

3 Magnificent Stocks That Could Double or More by 2030

Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many Western countries.

Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027

Bristol-Myers

Moderna

Biotech stocks are one of the hottest investing opportunities in the stock marketlately. The optimism surrounding the industry is evident in the SPDR S&PBiotech ETF's (NYSEARCA: XBI ) 25% bump in value over the past six months, outpacing broader market gains.

If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names

Ascendis Pharma

Cytokinetics

DexCom

Edwards Lifesciences

Tema Obesity & Cardiometabolic ETF

iShares Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

Medtronic

SPDR S&P 500 ETF Trust

Health Care Select Sector SPDR Fund

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

CRISPR Therapeutics' newly approved product could turn out to be very lucrative. Viking Therapeutics' leading candidate is rightfully grabbing plenty of attention.

Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics

Viking aims to challenge big pharma players Eli Lilly and Novo Nordisk in the multibillion-dollar weight loss drug market. It recently reported excellent clinical trial results for its injectable and oral tablet weight loss candidates.

Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.

Upstart biotech Viking Therapeutics is hoping to enter the weight loss treatment market. The company has released encouraging data from clinical trials for its candidate, VK2735.

Is it Too Late to Buy Viking Therapeutics Stock?

LOS ANGELES, April 5, 2024 /PRNewswire/ -- Viking Holdings Ltd ("Viking") today announced that it has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its ordinary shares. The number of ordinary shares to be offered and the price range for the proposed offering have not yet been determined.

Viking Files Registration Statement with SEC for Proposed Initial Public Offering

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals just commercialized its first medicine. Viking Therapeutics has a mid-stage candidate with great potential.

Better Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeutics

Viking Therapeutics is testing an oral version of its leading candidate. The biotech recently reported positive phase 1 results for this formulation.

Viking Therapeutics Just Announced More Positive Results: Time to Buy?

There's an ongoing gold rush for medicines that treat obesity. Viking Therapeutics already has two strong contenders in clinical trials.

1 Brand-New (Good) Reason to Buy Viking Therapeutics Stock Now

Transmedics Group Inc

Viking Therapeutics has delivered explosive gains in 2024, while TransMedics Group hasn't. Viking's share price could soar higher with a major catalyst within the next few months.

News for Viking Therapeutics Stock (VKTX)